SCHEMBL3267181

SCHEMBL3267181

CNC(=O)COC(=O)NCCC1CCN(c2cnc3ccccc3n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 6/20 0.44
SKP1 P63208 6/20 0.44
SKP2 Q13309 6/20 0.44
ACACB O00763 4/20 0.44
ACACA Q13085 4/20 0.44
HCAR2 Q8TDS4 1/20 0.43
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
HTR3A P46098 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.41
HTT P42858 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE10A Q9Y233 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265670 0.89 MAP4K4 (0.44) ACACBACACAMAPTPDE10ACHRM4
SCHEMBL3265727 0.89 HCAR2 (0.45) CKS1BSKP1SKP2ACACBACACA
SCHEMBL241775 0.88 ACACB (0.44) ACACBACACAALDH1A1PDE10AKCNH2
SCHEMBL3265668 0.86 CHRM4 (0.51) HTR3ACHRM4
SCHEMBL239096 0.85 CHRM4 (0.45) CKS1BSKP1SKP2ACACBACACA
SCHEMBL3266796 0.84 CHRM4 (0.48) ALDH1A1HPGDSMN1; SMN2CHRM4
SCHEMBL3268986 0.82 HSD11B1 (0.41) CKS1BSKP1SKP2ACACBACACA
SCHEMBL10202393 0.82 ACACB (0.42) ACACBACACACHRM4KCNH2
SCHEMBL239157 0.82 ACACB (0.42) ACACBACACACHRM4KCNH2
SCHEMBL1728004 0.82 HCAR2 (0.53) CKS1BSKP1SKP2HCAR2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CKS1B 1534/4885SKP1 4286/4885SKP2 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.